Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.38 |
| ▸ | TSHR | P16473 | 8/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.38 |
| ▸ | USP2 | O75604 | 7/20 | 0.38 |
| ▸ | CASP1 | P29466 | 6/20 | 0.38 |
| ▸ | CASP7 | P55210 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065151 | 0.91 | CYP1A2 (0.39) | MAPK14ALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL570302 | 0.89 | ALDH1A1 (0.40) | MAPK14ALDH1A1KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL569350 | 0.88 | HDAC1 (0.37) | MAPK14ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL570861 | 0.87 | KDM4E (0.36) | MAPK14KDM4EUSP2CASP1CASP7 | |
| SCHEMBL15085771 | 0.86 | TNIK (0.33) | TP53LMNAMAPT | |
| SCHEMBL15068355 | 0.85 | ALDH1A1 (0.41) | MAPK14ALDH1A1KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL10285379 | 0.85 | PDE10A (0.32) | TP53LMNAMAPT | |
| SCHEMBL570635 | 0.82 | CYP1A2 (0.40) | MAPK14ALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL15064441 | 0.81 | PDE1A (0.36) | MAPK14KDM4ELMNAMAPT | |
| SCHEMBL570249 | 0.81 | CYP1A2 (0.41) | MAPK14ALDH1A1KDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | MAPK14 2956/4885ALDH1A1 270/4885KDM4E 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.